Azzad Asset Management Inc. ADV Acquires 32,644 Shares of Novo Nordisk A/S $NVO

Azzad Asset Management Inc. ADV grew its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 49.7% during the first quarter, Holdings Channel.com reports. The institutional investor owned 98,290 shares of the company’s stock after purchasing an additional 32,644 shares during the quarter. Azzad Asset Management Inc. ADV’s holdings in Novo Nordisk A/S were worth $3,612,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of NVO. Boston Partners acquired a new position in shares of Novo Nordisk A/S during the 3rd quarter valued at $310,199,000. Price T Rowe Associates Inc. MD grew its holdings in Novo Nordisk A/S by 99.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 9,688,262 shares of the company’s stock worth $492,940,000 after purchasing an additional 4,836,285 shares during the period. Voloridge Investment Management LLC grew its holdings in Novo Nordisk A/S by 851.6% in the fourth quarter. Voloridge Investment Management LLC now owns 4,807,279 shares of the company’s stock worth $244,594,000 after purchasing an additional 4,302,126 shares during the period. Bank of Montreal Can increased its stake in Novo Nordisk A/S by 138.9% in the fourth quarter. Bank of Montreal Can now owns 2,525,827 shares of the company’s stock valued at $128,514,000 after purchasing an additional 1,468,409 shares in the last quarter. Finally, Quadrature Capital Ltd bought a new stake in Novo Nordisk A/S in the fourth quarter valued at $59,882,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on NVO. Nordea Equity Research raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Friday, June 19th. Wolfe Research assumed coverage on Novo Nordisk A/S in a research report on Thursday, March 26th. They issued a “peer perform” rating for the company. Weiss Ratings downgraded Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, April 22nd. HSBC reiterated a “hold” rating on shares of Novo Nordisk A/S in a report on Monday. Finally, Citigroup reissued a “neutral” rating on shares of Novo Nordisk A/S in a research note on Tuesday, May 12th. Five research analysts have rated the stock with a Buy rating, seventeen have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Novo Nordisk A/S presently has a consensus rating of “Hold” and an average target price of $65.56.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk launched Awiqli, the world’s first once-weekly basal insulin, in India, expanding its diabetes portfolio in one of the world’s largest and fastest-growing diabetes markets. The rollout could provide a new growth avenue and reinforces the company’s leadership in diabetes care. Article Title
• Positive Sentiment: Another report highlighted the India insulin launch as a meaningful innovation for diabetes treatment, which may improve investor sentiment around Novo Nordisk’s long-term pipeline and international expansion. Article Title
• Positive Sentiment: A separate piece said Novo Nordisk remains undervalued despite the Wegovy label update, suggesting the market may still be pricing in a cautious outlook even as the company preserves a strong long-term obesity-drug story. Article Title
• Neutral Sentiment: Novo Nordisk also expanded its collaboration with MAHE’s GBS in pharmacometrics, a strategic but likely modest near-term market-moving development. Article Title
• Neutral Sentiment: The company signed a pact with Vivani for a long-lasting semaglutide implant, which adds to its pipeline optionality but is still early-stage and not an immediate earnings driver. Article Title
• Negative Sentiment: Recent prescription-tracker data pointed to a slowdown in demand for the oral Wegovy pill in the U.S., raising concerns that growth in Novo Nordisk’s GLP-1 franchise may be cooling after a strong run. Article Title
• Negative Sentiment: The stock also came under pressure in recent trading after falling more than the broader market, reflecting investor caution around near-term GLP-1 growth trends and valuation. Article Title

Novo Nordisk A/S Stock Up 0.1%

Shares of NYSE:NVO opened at $48.93 on Friday. The business’s 50 day moving average is $45.39 and its 200 day moving average is $45.85. Novo Nordisk A/S has a 12-month low of $35.12 and a 12-month high of $71.79. The stock has a market cap of $218.48 billion, a price-to-earnings ratio of 11.49, a PEG ratio of 4.46 and a beta of 0.77. The company has a quick ratio of 0.56, a current ratio of 0.79 and a debt-to-equity ratio of 0.59.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Tuesday, March 31st. The company reported $1.03 EPS for the quarter. The business had revenue of $10.85 billion during the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%. On average, sell-side analysts forecast that Novo Nordisk A/S will post 3.38 earnings per share for the current fiscal year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.